RANCHO CORDOVA, Calif., Jan. 7, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Jeff Cauble, Chief Financial Officer, will present a company overview at the H.C. Wainwright BIOCONNECT 2021 Conference. The presentation will be available beginning January … Continued
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov 12, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the third quarter ended September 30, 2020 … Continued
Conference Call to be Held on November 12, 2020 RANCHO CORDOVA, Calif., November 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 … Continued
RANCHO CORDOVA, Calif., October 20, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) today announced that it has received notification from the United States Patent and Trademark Office (USPTO) of its intent to issue U.S. Patent No. 10,823,746 on November 3, for the Company’s new breakthrough lateral flow immunoassay test reader technology, the ThermoGenesis Reader. The … Continued
RANCHO CORDOVA, Calif., Sept 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The multi-pronged … Continued
RANCHO CORDOVA, Calif., Aug. 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management’s participation in the following investor conferences in September. September 1-4: LD Micro 500. Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis, will present … Continued
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 14, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the second quarter ended June 30, 2020 … Continued
RANCHO CORDOVA, Calif., August 13, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced that on August 12, the Company entered into a supply agreement with BioHit Healthcare (Hefei) Co., Ltd. to market, under the ThermoGenesis brand, its SARS-CoV-2 IgM/IgG Antibody … Continued
RANCHO CORDOVA, Calif., Aug. 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its second quarter earnings release and conference call for the quarter ended June 30, 2020, previously scheduled for Wednesday, August 12, … Continued
Conference Call to be Held on August 12, 2020 RANCHO CORDOVA, Calif., August 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 … Continued